Kekitiinwa, AdeodataSzubert, Alexander J.Katuramu, RichardMusiime, VictorKitaka, Sabrina BakeeraWalker, Ann SarahSenfuma, OscarGibb, Diana M.2023-02-212023-02-212017Kekitiinwa, A., Szubert, A. J., Spyer, M., Katuramu, R., Musiime, V., Mhute, T., ... & ARROW Trial Team. (2017). Virologic response to first-line efavirenz-or nevirapine-based anti-retroviral therapy in HIV-infected African children. The Pediatric infectious disease journal, 36(6), 588.https://doi.org/10.1097%2FINF.0000000000001505https://nru.uncst.go.ug/handle/123456789/7908Poorer virologic response to nevirapine vs efavirenz-based antiretroviral therapy (ART) has been reported in adult systematic reviews and pediatric studies. We compared drug discontinuation and viral load (VL) response in ART-naïve Ugandan/Zimbabwean children ≥3 years of age initiating ART with clinician-chosen nevirapine vs efavirenz in the ARROW trial. Predictors of suppression <80, <400 and <1000 copies/ml at 36, 48 and 144 weeks were identified using multivariable logistic regression with backwards elimination (p=0.1).enHIVchildrenantiretroviral therapyviral loadNNRTIArticle